OBJECTIVES: Activa®, Medtronic’s DBS, is an effective,safe and reversible therapy for Parkinson disease, essential tremor and dystonia. A cost analysis was perform to estimate the economic benefits related to 2 features of Activa PC® family, new DBS generation devices, and the net Budget impact (BI) for Spanish hospitals, compared to Kinetra®. METHODS: The 2 features: neurostimulator’s (NE) lower size and new stretchable extensions; both can avoid some adverse events (AEs) associated with Kinetra (no other benefits were considered). A literature search was done to retrieve safety studies. Selection criteria: AEs related with NE &/or the extension, their incidence and detailed treatment description. Health resource use was assigned to AEs treatment (Spanish hospital costs, Euros 2009): regional tariffs; acquisition costs. A net cost for each AEs was obtained, multiplying each AEs treatment incidence by its total cost. Total cost obtained with Activa PC®, compared to Kinetra®, corresponds to savings/patient. The net BI for Spanish hospitals was calculated: total incremental cost/Activa PC® treated patient instead of Kinetra® (considering AEs avoided and its savings). An AE incidence comparison was made as a sensitivity analysis (SA). RESULTS: 2 safety studies were selected. The 2 features could avoid 6 AEs, 2 related to NEs (hematoma in the NE implant site; infection/erosion); 4 with the extension (lead broke after a fall; extension fracture; skin ulceration in the connector; local discomfort). In total, avoiding these AEs involved 591€ saved/patient treated with Activa PC® family (SA obtained similar data). Including Activa PC® instead of Kinetra family in Spanish Hospitals involved a net BI per patient of €1.781. CONCLUSIONS: The new Activa PC family may avoid AEs related to the previous generation, Kinetra, with a decrease in the total cost per patient. The substitution of Kinetra® for Activa PC® family involves a small net budget impact per patient.